Public Sector Pension Investment Board Buys 89,350 Shares of Elevance Health, Inc. $ELV

Public Sector Pension Investment Board increased its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 515.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,682 shares of the company’s stock after purchasing an additional 89,350 shares during the quarter. Public Sector Pension Investment Board’s holdings in Elevance Health were worth $34,471,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ELV. Vanguard Group Inc. lifted its holdings in Elevance Health by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after buying an additional 704,790 shares in the last quarter. Sanders Capital LLC raised its position in shares of Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after acquiring an additional 1,152,440 shares during the last quarter. Artisan Partners Limited Partnership raised its position in shares of Elevance Health by 9.7% during the second quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock worth $1,429,498,000 after acquiring an additional 324,399 shares during the last quarter. Norges Bank acquired a new position in shares of Elevance Health during the second quarter valued at $1,148,379,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Elevance Health by 4.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock valued at $788,616,000 after acquiring an additional 112,020 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ELV. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Wells Fargo & Company cut their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Morgan Stanley reduced their price objective on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Finally, Barclays dropped their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Stock Up 1.8%

Elevance Health stock opened at $336.24 on Friday. The firm has a market capitalization of $74.21 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 1.84 and a beta of 0.50. The company’s 50 day simple moving average is $351.89 and its 200 day simple moving average is $331.31. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio is presently 27.23%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: MSN published a bullish take highlighting two reasons to like ELV (and one caution). The piece frames the company’s recent operational strength and valuation as positives that support the stock’s move higher. 2 reasons to like ELV (and 1 not so much)
• Positive Sentiment: Recent reported results: ELV beat Q3/Q4 consensus on EPS ($3.33 vs. $3.10) and posted ~9.6% revenue growth year-over-year; management set FY2026 EPS guidance around $25.50 — these items underpin investor confidence in near-term profitability and support valuation (PE ~13.4).
• Neutral Sentiment: Zacks issued a mixture of tweaks to quarterly models — it raised a few near‑term quarter estimates (e.g., Q4 2027 and Q3 2027 uplift) while leaving a “Hold” rating in place. Those isolated raises offer limited upside until broader guidance/trajectory is confirmed.
• Negative Sentiment: Zacks materially trimmed several near‑term and full‑year forecasts: FY2026 down to ~$25.53 (from ~$29.01) and FY2027 to ~$28.40 (from ~$31.89), plus multiple Q1/Q2 quarter cuts. The cuts reduce forward EPS expectations and could weigh on the stock if other analysts follow suit or if management doesn’t reaffirm stronger guidance.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.